Second-Line Gemcitabine Plus Nab-Paclitaxel for Patients with Unresectable Advanced Pancreatic Cancer after First-Line FOLFIRINOX Failure

FOLFIRINOX (FX) and gemcitabine (GEM) plus nab-paclitaxel (GnP) have been reported as effective regimens for unresectable advanced pancreatic cancer (APC). FX may be more effective but is also associated with more adverse events (AEs). Therefore, first-line treatment with FX followed by second-line...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:J Clin Med
Autores principales: Mita, Naoki, Iwashita, Takuji, Uemura, Shinya, Yoshida, Kensaku, Iwasa, Yuhei, Ando, Nobuhiro, Iwata, Keisuke, Okuno, Mitsuru, Mukai, Tsuyoshi, Shimizu, Masahito
Formato: Artigo
Lenguaje:Inglês
Publicado: MDPI 2019
Materias:
Article
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC6616879/
https://ncbi.nlm.nih.gov/pubmed/31146420
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/jcm8060761
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares